Abstract
The purpose of this research was to use our previously validated dynamic injection apparatus as a rapid method for screening pH-adjusted formulations of a new vancomycin analog, Van-An, for their potential to precipitate upon dilution. In 1 vial, Van-An was reconstituted according to the manufacturer’s instructions. In a separate vial, the Van-An formulation’s existing phosphate buffer species was supplemented with acetate buffer, which has a pKa in the desired range: between the pH values of the formulation (pH 3.9) and blood (pH 7.4). The formulations were injected using the dynamic injection apparatus into a flowing stream of isotonic Sorensen’s phosphate buffer at rates of 0.25, 0.5, 1, and 2 mL/min. The peaks obtained with the spectrophotometer were reproducible for each injection rate/formulation combination. For the phosphate-buffered formulation, the least amount of precipitation was obtained at the 0.25 mL/min injection rate. Acetate buffer was able to substantially reduce such precipitation, even at the highest injection rate. The opacity peaks for the formulation with the acetate addition were significantly smaller (P<.05) than those obtained for the unaltered formulation at all 4 injection rates. The results suggest that acetate is a better buffer species than phosphate for the pH range defined. Furthermore, we present evidence to support a generally applicable approach to screening new formulations of drug products that may be clinically useful for reducing the incidence of phlebitis in humans.
Keywords: Precipitation, phlebitis, pH, solubility, prediction, probability, sensitivity, specificity, in vitro model, blood surrogate, buffer species
Full Text
The Full Text of this article is available as a PDF (182.4 KB).
References
- 1.Hadaway L, Chamallas SN. Vancomycin. J Infus Nurs. 2003;26:278–284. doi: 10.1097/00129804-200309000-00003. [DOI] [PubMed] [Google Scholar]
- 2.Takács-Novák K, Noszál B, Tokes-Kovesdi M, Szasz G. Acid base properties and proton-speciation of vancomycin. Int J Pharm. 1993;89:261–263. doi: 10.1016/0378-5173(93)90252-B. [DOI] [Google Scholar]
- 3.Malabarba A, Ciabatti R. Glycopeptide derivatives. Curr Med Chem. 2001;8:1759–1773. doi: 10.2174/0929867013371716. [DOI] [PubMed] [Google Scholar]
- 4.Salaria M. Teicoplanin. Indian Pediatr. 2001;38:372–375. [PubMed] [Google Scholar]
- 5.Douchin K, Shaw J, Spencer E, Seroogy J, Barriere S, Wilbraham D. Single dose pharmacokinetics (PK) of telavancin (TLV) in healthy elderly subjects. Clin Microbiol Infect. 2004;10:275–275. [Google Scholar]
- 6.Douchin K, Shaw J, Spencer E, Seroogy J, Barriere S, Wilbraham D. Single dose pharmacokinetics (PK) of telavancin (TLV) in subjects with renal dysfunction. Clin Microbiol Infect. 2004;10:276–276. [Google Scholar]
- 7.Internet press release from Biospase Beat. Biotechnology and Pharmaceutical News. Available at: http://www.biospace.com/news_ story.cfm?StoryID=14456320&full=1. Accessed: December 28, 2004.
- 8.Targocid for Injection package insert. Available at: http://home. intekom.com/pharm/roussel/targocid.html. Accessed: December 28, 2004.
- 9.Van Bambeke F, Van Laethem Y, Courvalin P, Tulkens PM. Glycopeptide antibiotics: from conventional molecules to new derivatives. Drugs. 2004;64:913–936. doi: 10.2165/00003495-200464090-00001. [DOI] [PubMed] [Google Scholar]
- 10.Taxis K, Barber N. Ethnographic study of incidence and severity of intravenous drug errors. BMJ. 2003;326:1–4. doi: 10.1136/bmj.326.7391.684. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Lanbeck P, Odenholt I, Paulsen O. Antibiotics differ in their tendency to cause infusion phlebitis: a prospective observational study. Scand J Infect Dis. 2002;34:512–519. doi: 10.1080/00365540110080908. [DOI] [PubMed] [Google Scholar]
- 12.Johnson JLH, He Y, Yalkowsky SH. Prediction of precipitation-induced phlebitis: a statistical validation of an in vitro model. J Pharm Sci. 2003;92:1574–1581. doi: 10.1002/jps.10396. [DOI] [PubMed] [Google Scholar]
- 13.Rowland M, Tozer TM. Clinical Pharmacokinetics: Concepts and Applications. Baltimore, MD: Lippincott Williams & Wilkins; 1995. pp. 138–138. [Google Scholar]
- 14.Abbott Laboratories NDA no. 13-025/S-035 submission. Available at: http://www.fda.gov/cder/ogd/rld/13025S35.pdf. Accessed: November 28, 2004.
- 15.Surakitbanharn Y, Simamora P, Ward GH, Yalkowsky SH. Precipitation of pH solubilized phenytoin. Int J Pharm. 1994;109:27–33. doi: 10.1016/0378-5173(94)90118-X. [DOI] [Google Scholar]
- 16.Davio SR, McShane MM, Kaluk TJ, Zaya RM, Cole SL. Precipitation of the renin inhibitor ditekiren upon i.v. infusion: in vitro studies and their relationship to in vivo precipitation in the cynomolgus monkey. Pharm Res. 1991;8:80–83. doi: 10.1023/A:1015886424586. [DOI] [PubMed] [Google Scholar]
- 17.Greenfield JC, Loux SJ, Sood VK, Jenkins KM, Davio SR. In vitro evaluation of the plasma and blood compatibility of a parenteral formulation for ditekiren, a novel renin inhibitor pseudopeptide. Pharm Res. 1991;8:475–479. doi: 10.1023/A:1015847027254. [DOI] [PubMed] [Google Scholar]
- 18.Faulding Pharmaceuticals Editorial: vancomycin injection. Pharm J. 1999;263:880–880. [Google Scholar]
- 19.Kastango ES, Hadaway L. New perspectives on vancomycin use in home care, part 2: delivery systems. Int J Pharm Comp. 2002;6:55–57. [PubMed] [Google Scholar]